This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Piscopo, D. M. Articles by Hinds, P. W. Search for Related Content PubMed PubMed Citation Articles by Piscopo, D. M. Articles by Hinds, P. W.

A Role for the Cyclin Box in the Ubiquitin-Mediated Degradation of Cyclin G1

Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts

Requests for reprints: Philip W. Hinds, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111. Phone: 617-636-7947; Fax: 617-636-7813; E-mail: phinds{at}tuftsmedicalcenter.org.

Key Words: cyclin G1 • CDK • p53 • MDM2 • ubiquitination

Cyclin G1 was identified as a transcriptional target of p53 that encodes a protein with strong homology to the cyclin family of cell cycle regulators. We show that either ectopically expressed or endogenous cyclin G1 protein is very unstable, undergoes modification with ubiquitin, and is likely degraded by the proteasome. Ectopic cyclin G1 protein stability is increased by cyclin box mutation or by association with inactive cyclin-dependent kinase (CDK) subunits, suggesting that a function of cyclin G1 as a CDK regulator may be required for its rapid turnover. Furthermore, cyclin G1 and the cyclin box mutant interact with and are ubiquitinated by MDM2, another transcriptional target of p53 that acts as a negative regulator of p53 stability. These data suggest that the cyclin box has a role in the proteasome-mediated degradation of cyclin G1 and thus suggest a putative role for a CDK in cyclin G1 metabolism and function. [Cancer Res 2008;68(14):5581–90]